Evidence map›Paper›PMID 37395655›Full record

ArticleJournal of clinical microbiology2023

RADx-UP Testing Core: Access to COVID-19 Diagnostics in Community-Engaged Research with Underserved Populations.

Shanti Narayanasamy, Timothy H Veldman, Mark J Lee, William A Glover, L Gayani Tillekeratne, Coralei E Neighbors, Barrie Harper, Vidya Raghavan, Scott W Kennedy, Miranda Carper and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Shanti NarayanasamyDivision of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-6667-2868
Timothy H VeldmanDuke Global Health Institute, Durham, North Carolina, USA.
Mark J LeeDepartment of Pathology, School of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
William A GloverNorth Carolina State Laboratory of Public Health, North Carolina Department of Health and Human Services, Raleigh, North Carolina, USA.
L Gayani TillekeratneDivision of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA.
Coralei E NeighborsHubert-Yeargan Center for Global Health, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-0367-2983
Barrie HarperDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Vidya RaghavanDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Scott W KennedyDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Miranda CarperDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Thomas DennyDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Ephraim L TsalikDivision of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA.
Megan E RellerDivision of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA.
Warren A KibbeDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.
Giselle CorbieCenter for Health Equity Research, University of North Carolina, Chapel Hill, North Carolina, USA.
Michael Cohen-WolkowiezDuke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Christopher W WoodsDivision of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA.
Cathy A PettiDivision of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA.
Duke University · USDuke Institute for Health Innovation · USNC Department of Health and Human Services · USUniversity of North Carolina at Chapel Hill · US

Funding

RADx-UP SAY YES COVID Test Study (S4)U24MD016258 · NIMHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL, DAVE, GAURAV J · 2020 to 2023
$116.7M
Global Pediatric Clinical Trials NetworkU18FD006298 · FDA · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL, HORNIK, CHRISTOPH · 2017 to 2021
$5.5M
Mentoring in Clinical Pharmacology and Early Phase TrialsK24AI143971 · NIAID · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2019 to 2023
$895k
FDA HHS U18 FD006298NIAID NIH HHS K24 AI143971NIMHD NIH HHS U24 MD016258
6 · The paper itself

Abstract

Research on the COVID-19 pandemic revealed a disproportionate burden of COVID-19 infection and death among underserved populations and exposed low rates of SARS-CoV-2 testing in these communities. A landmark National Institutes of Health (NIH) funding initiative, the Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, was developed to address the research gap in understanding the adoption of COVID-19 testing in underserved populations. This program is the single largest investment in health disparities and community-engaged research in the history of the NIH. The RADx-UP Testing Core (TC) provides community-based investigators with essential scientific expertise and guidance on COVID-19 diagnostics. This commentary describes the first 2 years of the TC's experience, highlighting the challenges faced and insights gained to safely and effectively deploy large-scale diagnostics for community-initiated research in underserved populations during a pandemic. The success of RADx-UP shows that community-based research to increase access and uptake of testing among underserved populations can be accomplished during a pandemic with tools, resources, and multidisciplinary expertise provided by a centralized testing-specific coordinating center. We developed adaptive tools to support individual testing strategies and frameworks for these diverse studies and ensured continuous monitoring of testing strategies and use of study data. In a rapidly evolving setting of tremendous uncertainty, the TC provided essential and real-time technical expertise to support safe, effective, and adaptive testing. The lessons learned go beyond this pandemic and can serve as a framework for rapid deployment of testing in response to future crises, especially when populations are affected inequitably.

Indexed as

COVID-19COVID-19 TestingHumansPandemicsSARS-CoV-2Vulnerable PopulationsCOVID-19diagnosticsequityRADx-UPunderserved communities

Identifiers

PMID37395655
PMCPMC10446854
OpenAlexW4382918855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.